Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Co-administered Varicella and Influenza Vaccines in Children
NCT06987942Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of varicella virus vaccine live in varicella (VZV) (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Geometric Mean Titer of Varicella Zoster Virus Antibody at Day 30 and Geometric Mean Titer of Hemagglutination Inhibition Antibody at Day 30. Started Sep 2024; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT06987942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987942.